2025-07-17 イェール大学
<関連情報>
- https://medicine.yale.edu/news-article/once-monthly-obesity-medication-shows-promise-for-those-with-and-without-type-2-diabetes/
- https://www.nejm.org/doi/full/10.1056/NEJMoa2504214?query=featured_home
肥満治療のための月1回投与マリデバート・カフラグチド — フェーズ2試験 Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
Ania M. Jastreboff, M.D., Ph.D., Donna H. Ryan, M.D., Harold E. Bays, M.D., Peter R. Ebeling, M.D., Mia G. Mackowski, Pharm.D., Nisha Philipose, B.Pharm., M.Sc., Leorah Ross, M.D., Ph.D., Yimeng Liu, M.P.H., Ph.D., Cassandra E Burns, Ph.D., Siddique A. Abbasi, M.D., and Nicola Pannacciulli, M.D., Ph.D., for the MariTide Phase 2 Obesity Trial Investigators
The New England Journal of Medicine Published: June 23, 2025
DOI: 10.1056/NEJMoa2504214
Abstract
Background
Maridebart cafraglutide (known as MariTide) is a long-acting peptide–antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropic polypeptide receptor antagonism and that is intended for the treatment of obesity.
Methods
We conducted a phase 2, double-blind, randomized, placebo-controlled, dose-ranging trial that included 11 groups as two cohorts. Participants with obesity (obesity cohort) were randomly assigned in a 3:3:3:2:2:2:3 ratio to receive maridebart cafraglutide subcutaneously at a dose of 140, 280, or 420 mg every 4 weeks without dose escalation; 420 mg every 8 weeks without dose escalation; 420 mg every 4 weeks with 4-week dose escalation; 420 mg every 4 weeks with 12-week dose escalation; or placebo. Participants with obesity with type 2 diabetes (obesity–diabetes cohort) were randomly assigned in a 1:1:1:1 ratio to receive maridebart cafraglutide at a dose of 140, 280, or 420 mg every 4 weeks (all without dose escalation) or placebo. The primary end point was the percent change in body weight from baseline to week 52.
Results
We enrolled 592 participants. In the obesity cohort (465 participants; female sex, 63%; mean age, 47.9 years; mean body-mass index [BMI, the weight in kilograms divided by the square of the height in meters], 37.9), the mean percent change in body weight from baseline to week 52 on the basis of the treatment policy estimand (intention-to-treat approach) ranged from -12.3% (95% confidence interval [CI], -15.0 to -9.7) to -16.2% (95% CI, -18.9 to -13.5) with maridebart cafraglutide, as compared with -2.5% (95% CI, -4.2 to -0.7) with placebo. In the obesity–diabetes cohort (127 participants; female sex, 42%; mean age, 55.1 years; mean BMI, 36.5), the mean percent change in body weight from baseline to week 52 on the basis of the treatment policy estimand ranged from -8.4% (95% CI, -11.0 to -5.7) to -12.3% (95% CI, -15.3 to -9.2) with maridebart cafraglutide, as compared with -1.7% (95% CI, -2.9 to -0.6) with placebo. The mean change in the glycated hemoglobin level on the basis of the treatment policy estimand in this cohort was -1.2 to -1.6 percentage points in the maridebart cafraglutide groups and 0.1 percentage points in the placebo group. Gastrointestinal adverse events were common with maridebart cafraglutide, although less frequent with dose escalation and a lower starting dose. No unexpected safety signals emerged.
Conclusions
In this phase 2 trial, once-monthly maridebart cafraglutide resulted in substantial weight reduction in participants with obesity with or without type 2 diabetes. (Funded by Amgen; ClinicalTrials.gov number, NCT05669599.)
